CN105646471A - 细胞凋亡蛋白抑制剂的固体口服制剂和晶形 - Google Patents

细胞凋亡蛋白抑制剂的固体口服制剂和晶形 Download PDF

Info

Publication number
CN105646471A
CN105646471A CN201610031620.0A CN201610031620A CN105646471A CN 105646471 A CN105646471 A CN 105646471A CN 201610031620 A CN201610031620 A CN 201610031620A CN 105646471 A CN105646471 A CN 105646471A
Authority
CN
China
Prior art keywords
preparation
compound
crystal form
ethyl
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610031620.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·塔库尔
D·杨
冯丽丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105646471(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105646471A publication Critical patent/CN105646471A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201610031620.0A 2009-08-12 2010-08-11 细胞凋亡蛋白抑制剂的固体口服制剂和晶形 Pending CN105646471A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
US61/274,051 2009-08-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080035867.0A Division CN102471331B (zh) 2009-08-12 2010-08-11 细胞凋亡蛋白抑制剂的固体口服制剂和晶形

Publications (1)

Publication Number Publication Date
CN105646471A true CN105646471A (zh) 2016-06-08

Family

ID=42937834

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610031620.0A Pending CN105646471A (zh) 2009-08-12 2010-08-11 细胞凋亡蛋白抑制剂的固体口服制剂和晶形
CN201080035867.0A Expired - Fee Related CN102471331B (zh) 2009-08-12 2010-08-11 细胞凋亡蛋白抑制剂的固体口服制剂和晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080035867.0A Expired - Fee Related CN102471331B (zh) 2009-08-12 2010-08-11 细胞凋亡蛋白抑制剂的固体口服制剂和晶形

Country Status (24)

Country Link
US (4) US8623385B2 (https=)
EP (1) EP2464644A1 (https=)
JP (3) JP2013501751A (https=)
KR (2) KR20180020315A (https=)
CN (2) CN105646471A (https=)
AR (1) AR077869A1 (https=)
AU (4) AU2010283748A1 (https=)
BR (1) BR112012003118A2 (https=)
CA (1) CA2769616A1 (https=)
CL (1) CL2012000349A1 (https=)
CO (1) CO6612189A2 (https=)
IL (1) IL217760A0 (https=)
IN (1) IN2012DN00858A (https=)
MA (1) MA33511B1 (https=)
MX (2) MX2012001844A (https=)
MY (1) MY160475A (https=)
PE (2) PE20170777A1 (https=)
PH (1) PH12014501890A1 (https=)
RU (1) RU2671196C1 (https=)
SG (1) SG177713A1 (https=)
TN (1) TN2012000026A1 (https=)
TW (1) TWI607006B (https=)
WO (1) WO2011018474A1 (https=)
ZA (1) ZA201200390B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
DK1836201T4 (da) * 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Also Published As

Publication number Publication date
MY160475A (en) 2017-03-15
US20180370960A1 (en) 2018-12-27
PH12014501890B1 (en) 2015-09-14
KR20180020315A (ko) 2018-02-27
BR112012003118A2 (pt) 2016-02-23
JP2018172403A (ja) 2018-11-08
PH12014501890A1 (en) 2015-09-14
MX351274B (es) 2017-10-06
TN2012000026A1 (en) 2013-09-19
CN102471331A (zh) 2012-05-23
US8623385B2 (en) 2014-01-07
US9540363B2 (en) 2017-01-10
CA2769616A1 (en) 2011-02-17
RU2012108931A (ru) 2013-09-27
AR077869A1 (es) 2011-09-28
TW201118091A (en) 2011-06-01
MA33511B1 (fr) 2012-08-01
IL217760A0 (en) 2012-03-29
PE20121132A1 (es) 2012-09-04
CO6612189A2 (es) 2013-02-01
TWI607006B (zh) 2017-12-01
AU2017254950B2 (en) 2018-09-20
MX2012001844A (es) 2012-02-29
US10093665B2 (en) 2018-10-09
AU2017254950A1 (en) 2017-11-23
CL2012000349A1 (es) 2012-09-07
WO2011018474A8 (en) 2011-09-22
IN2012DN00858A (https=) 2015-07-10
PE20170777A1 (es) 2017-07-04
AU2014213533A1 (en) 2014-09-04
US20170081319A1 (en) 2017-03-23
RU2671196C1 (ru) 2018-10-30
ZA201200390B (en) 2012-10-31
US20120128742A1 (en) 2012-05-24
EP2464644A1 (en) 2012-06-20
AU2010283748A1 (en) 2012-02-09
CN102471331B (zh) 2016-01-13
JP2013501751A (ja) 2013-01-17
AU2016203145A1 (en) 2016-06-02
KR20120048008A (ko) 2012-05-14
SG177713A1 (en) 2012-02-28
US20140093570A1 (en) 2014-04-03
WO2011018474A1 (en) 2011-02-17
JP2016179976A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
US12595254B2 (en) Crystal form of Resmetirom, preparation method therefor, and use thereof
JP7659097B2 (ja) Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
WO2008017398A2 (en) Polymorphic forms of rosiglitazone base
CN105646471A (zh) 细胞凋亡蛋白抑制剂的固体口服制剂和晶形
US11236066B2 (en) Crystalline forms of niraparib tosylate
JP2020090471A (ja) アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
EP4149934A1 (en) Crystalline forms and formulations of a vcp/p97 inhibitor
JP7634297B2 (ja) エフィナコナゾール経口用組成物
CN102349889A (zh) 一种含有决奈达隆的组合物
JP6668666B2 (ja) イルベサルタンを含有する医薬組成物及びその製造方法
JP2023552556A (ja) テナパノルの経口製剤
PL223392B1 (pl) Sposób wytwarzania granulatu zawierającego metanosulfonian imatinibu w odmianie krystalicznej α jako jedyny składnik
HK40007684B (en) Preparation containing benzimidazole derivative
AU2018203509A1 (en) Novel crystalline forms of Ibrutinib

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160608

WD01 Invention patent application deemed withdrawn after publication